AstraZeneca’s Calquence (acalabrutinib) Receives the MHLW’s Approval for Treatment-Naïve Chronic Lymphocytic Leukaemia
- The MHLW has approved Calquence for treatment-naïve CLL incl. SLL. The approval was based on the results from the 2 clinical trials, incl. the P-III trial (ELEVATE-TN) evaluating Calquence (100mg, BID) as monotx. or in combination with obinutuzumab vs chlorambucil + obinutuzumab in a ratio (1:1:1) in 535 adult patients
- The results showed PFS benefits, and a safety & tolerability profile consistent with the known profile for Calquence, 89% reduction in risk of disease progression or death in the combination therapy, and 79% as a monotx. at a median follow-up of 58.2mos.
- The therapy was approved in the US for CLL & SLL while in the EU for CLL along with multiple other countries globally. The therapy was also approved in the US & other countries for MCL
Ref: AstraZeneca | Image: AstraZeneca
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.